DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805)

Information source: University of North Carolina, Chapel Hill
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Acute HIV Infection; HIV Infections

Intervention: Atripla (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: University of North Carolina, Chapel Hill

Official(s) and/or principal investigator(s):
Cynthia Gay, MD, MPH, Principal Investigator, Affiliation: University of North Carolina, Chapel Hill

Summary

This is a pilot study of treatment of acute HIV infection with a once daily regimen of Emtricitabine, Tenofovir and Efavirenz. The primary objectives of this study are: 1. To determine the safety and tolerability, and the virologic and immunologic efficacy of FTC, TDF, and efavirenz given once daily to patients with acute HIV infection. 2. To assess the impact of once daily therapy combined with a standardized adherence program on treatment adherence, virologic suppression, and rate of viral load decline in blood and infectious fluids (semen, cervico-vaginal secretions). 3. To define the prevalence of genotypic and phenotypic resistance to antiretroviral agents among persons diagnosed with acute HIV infection in the Southeastern United States.

Clinical Details

Official title: CID 0805 - Treatment of Acute HIV Infection With a Once Daily Regimen of Emtricitabine, Tenofovir and Efavirenz - A Pilot Study of Response to Therapy and HIV Pathogenesis

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: To determine the safety and tolerability, and the virologic and immunologic efficacy of FTC/TDF, and efavirenz or the fixed-dose combination of efavirenz/FTC/TDF (Atripla) given once daily to patients with acute HIV infection.

Secondary outcome:

To assess impact of once daily therapy combined with a standardized adherence program on treatment adherence, virologic suppression, and rate of viral load decline in blood and infectious fluids (cerebrospinal fluid, semen, and vaginal secretions).

To define the prevalence of genotypic and phenotypic resistance to antiretroviral agents among persons diagnosed with acute HIV infection in the Southeastern United States.

Detailed description: Hypothesis: Once daily HAART with FTC/TDF (FDC, Truvada) + EFV administered as a single dose pill called Atripla will reduce viral replication to <400 copies RNA/ml plasma in blood and other body compartments in patients with acute HIV infection, reducing infectivity, and permitting generation of HIV-specific immune responses. The treatment regimen will be well tolerated and any lipid profile changes will be modest during treatment follow-up. A coordinated program of counseling and support will facilitate adherence and promote successful therapy. Prevalence of transmitted drug resistant HIV-1 will be assessed. Study Design: Multi-center, prospective, single-arm pilot study of FTC/TDF/EFV in patients with acute HIV infection. Study sites will be members of the Duke-UNC Acute HIV Infection Study Consortium. Patients will be followed intensively for the first year with continued follow-up for an additional year pending developments on treatment cessation approaches for patients with suppressed virus and effective immune responses.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria: 1. Diagnosis of acute HIV infection as defined by protocol. 2. The following laboratory parameters verified within 30 days of study entry:

- Bilirubin

- ALT/AST

- Absolute neutrophil count (ANC) >/= 500cells/mm3

- Platelet count >/= 25,000 cells/mm3

- Hemoglobin >/= 8. 5g/dL for men and >/= 8. 0 g/dL for women

- Calculated creatinine clearance (Cockcroft-Gault formula) >/= 50mL/min:

CrCl = (140-age) x body weight (kg) (x 0. 85 if female)/ Serum creatinine [mg/dL] x (72) 3. All women of child-bearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of bHCG) within 72 hours prior to start of study medication. WOCBP is defined as any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy), who is not postmenopausal (defined as amenorrhea >/=12 consecutive months), or is on hormone replacement therapy (HRT) with documented plasma follicle-stimulating hormone level >/=35mLU/mL. Women who are using oral, implanted, or injectable contraceptive hormones or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy or practicing abstinence or where partner is sterile (e. g., vasectomy), should be considered to be of child bearing potential; 4. Be willing to use two effective forms of contraception throughout study. Barrier contraception should always be used in combination with other methods of contraception (oral or other hormonal contraceptives); 5. Weigh >/= 40 kg; Exclusion Criteria: 1. A life expectancy less than twelve months. 2. Women who are pregnant or breastfeeding. 3. Women with a positive pregnancy test on enrollment or prior to study drug administration. 4. WOCBP who are unwilling or unable to use two acceptable methods to avoid pregnancy for the entire study period 5. WOCBP using a prohibited contraceptive method 6. Hypersensitivity to any component of the formulation of study drugs. 7. A clinically important illness not explicitly excluded by the protocol, a physical or psychiatric disability, or a laboratory abnormality that might place the patient at increased risk by being exposed to the medications in this study or which might confound the interpretation of this investigation. 8. Proven or suspected acute hepatitis within 30 days prior to study entry (this excludes liver inflammation related to acute HIV infection). 9. Intractable diarrhea (>/=6 loose stools/day for at least 7 consecutive days) within 30 days prior to study entry or vomiting lasting more than 4 days within one month prior to dosing (this excludes symptoms attributed to acute HIV infection). 10. An active AIDS-defining opportunistic infection or disease (for the purpose of this study, a CD4 count - The following medications are expressly prohibited during the course of the

trial: Astemizole, cisapride, ergot derivatives, hydroxyurea, midazolam, thalidomide, triazolam, vincristine, zalcitabine, ribavirin, doxorubicin, Voriconazole, St. John's wort or any medications that are contraindicated for concomitant use as described in the current product information packet insert for the ARV therapies used.

Locations and Contacts

The University of North Carolina - Chapel Hill, Chapel Hill, North Carolina 27599, United States

Duke University, Durham, North Carolina 27707, United States

Additional Information

IAS Conference Abstract-Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection

Starting date: January 2005
Last updated: September 9, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017